Trends in the use of androgen deprivation in prostate cancer

The aim of this study was to assess current management of prostate cancer patients with elevated prostate-specific antigen (PSA) among Finnish urologists and oncologists. Four case scenarios were presented: postprostatectomy PSA relapse, postradiotherapy (RT) relapse with a slowly or rapidly rising...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2004-06, Vol.43 (4), p.382-387
Main Authors: Salminen, Eeva K., Wickström, Jan-Erik, Vahlberg, Tero, Duchesne, Gillian M.
Format: Article
Language:English
Subjects:
Adult
Aged
Androgen Antagonists - administration & dosage
Antineoplastic Agents, Hormonal - administration & dosage
Attitude of Health Personnel
Australia
Chemotherapy, Adjuvant
Finland
Humans
Male
Middle Aged
Neoplasm Staging
Practice Patterns, Physicians
Prospective Studies
Prostate-Specific Antigen - analysis
Prostatectomy - methods
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Risk Assessment
Surveys and Questionnaires
Survival Rate
Treatment Outcome
Urology - standards
Urology - trends
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to assess current management of prostate cancer patients with elevated prostate-specific antigen (PSA) among Finnish urologists and oncologists. Four case scenarios were presented: postprostatectomy PSA relapse, postradiotherapy (RT) relapse with a slowly or rapidly rising PSA, elderly patients prior to treatment. Management preferences and the use of androgen deprivation (AD) in prostate cancer were surveyed. Eighty-two informative replies, 60 from 90 practicing urologists (67%) and 22 from 70 practicing oncologists (31%) were received. For postprostatectomy relapse, salvage RT or follow-up until significant rise of PSA were the favored recommendations. For post RT with slowly or rapidly rising PSA and treatment of non-radical cases an active approach with even small PSA rises and immediate androgen deprivation were favored. For intervention, the recommended PSA border values ranged from 0.5 to >100 ng/mL. More research is needed focusing on criteria and timing of AD in the treatment of prostate cancer.
ISSN:0284-186X
1651-226X
DOI:10.1080/02841860410029500